Sana Biotechnology (NASDAQ:SANA) Earns Buy Rating from Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group began coverage on shares of Sana Biotechnology (NASDAQ:SANA - Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set a "buy" rating and a $7.00 price target on the stock. Jefferies Financial Group's price target would indicate a potential upside of 138.91% from the stock's previous close.

Other equities analysts have also issued research reports about the company. TD Cowen raised Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright upped their price target on Sana Biotechnology from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $12.25.

Sana Biotechnology Trading Up 10.6 %

Shares of SANA traded up $0.28 during trading hours on Friday, hitting $2.93. 2,989,692 shares of the stock traded hands, compared to its average volume of 2,977,744. Sana Biotechnology has a 1-year low of $1.52 and a 1-year high of $10.50. The firm has a market capitalization of $654.18 million, a PE ratio of -2.09 and a beta of 1.63. The business has a fifty day moving average of $3.03 and a 200-day moving average of $3.27.

Remove Ads

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares of the company's stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 31.10% of the company's stock.

Institutional Investors Weigh In On Sana Biotechnology

Large investors have recently bought and sold shares of the company. Cerity Partners LLC bought a new stake in Sana Biotechnology in the fourth quarter valued at approximately $25,000. Tower Research Capital LLC TRC boosted its holdings in shares of Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after buying an additional 10,548 shares during the period. Syon Capital LLC acquired a new position in shares of Sana Biotechnology in the fourth quarter valued at approximately $27,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Sana Biotechnology in the third quarter valued at approximately $29,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Sana Biotechnology in the fourth quarter valued at approximately $29,000. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.